<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy of the-state-of-the-art modalities of systemic and regional chemo-infusion with oxalyplatin (FOLFOX) and irinotecan (FOLFIRI) (162) was compared </plain></SENT>
<SENT sid="1" pm="."><plain>Objective response to the former was 40.8%, to the latter--11.9% (p = 0.0002); survival before intrasplenic relapse--9 and 5 months, respectively, (p = 0.0005); overall survival before relapse (median 7 and 4 months, respectively, (p = 0.01) </plain></SENT>
<SENT sid="2" pm="."><plain>The rate of survival before intrasplenic relapse in the systemic chemo-infusion group was significantly higher (median 10.5 vs. 8.1 months, respectively, (p = 0.03) </plain></SENT>
<SENT sid="3" pm="."><plain>No significant differences in overall survival were reported (median 15 vs. 13 months, respectively, in the latter group (p = 0.72) </plain></SENT>
</text></document>